Exaggeration of PFS by blinded, independent, central review (BICR)
A Stone(Stone Age Institute), Alvarez Sabin(AstraZeneca (United Kingdom)), Jonathan W. Bartlett(Uppsala University), Val Gebski(The University of Sydney), Richard Davidson(AstraZeneca (United Kingdom)), Ralph Bloomfield(AstraZeneca (United Kingdom))
Cited by 27
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842